BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429-438. [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P. ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer. Int J Mol Sci 2018;19:E868. [PMID: 29543757 DOI: 10.3390/ijms19030868] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
2 Tanaka K, Miyata H, Yamasaki M, Sugimura K, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Circulating miR-200c Levels Significantly Predict Response to Chemotherapy and Prognosis of Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Cancer. Ann Surg Oncol 2013;20:607-15. [DOI: 10.1245/s10434-013-3093-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.7] [Reference Citation Analysis]
3 Guo SL, Peng Z, Yang X, Fan KJ, Ye H, Li ZH, Wang Y, Xu XL, Li J, Wang YL, Teng Y, Yang X. miR-148a promoted cell proliferation by targeting p27 in gastric cancer cells. Int J Biol Sci 2011;7:567-74. [PMID: 21552422 DOI: 10.7150/ijbs.7.567] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 7.0] [Reference Citation Analysis]
4 Hong L, Han Y, Lu Q, Zhang H, Zhao Q, Wu K, Fan D. Drug resistance-related microRNAs in esophageal cancer. Expert Opin Biol Ther 2012;12:1487-94. [PMID: 22827640 DOI: 10.1517/14712598.2012.711309] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
5 Li H, Xu H, Shen H, Li H. microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells. Oncol Lett 2014;7:183-8. [PMID: 24348845 DOI: 10.3892/ol.2013.1644] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
6 Hamidi AA, Zangoue M, Kashani D, Zangouei AS, Rahimi HR, Abbaszadegan MR, Moghbeli M. MicroRNA-217: a therapeutic and diagnostic tumor marker. Expert Rev Mol Diagn 2021;:1-16. [PMID: 34883033 DOI: 10.1080/14737159.2022.2017284] [Reference Citation Analysis]
7 Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, Yang K. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277-286. [PMID: 24909356 DOI: 10.1111/cpr.12109] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
8 Amin M, Lam AK. Current perspectives of mi-RNA in oesophageal adenocarcinoma: Roles in predicting carcinogenesis, progression and values in clinical management. Exp Mol Pathol 2015;98:411-8. [PMID: 25746664 DOI: 10.1016/j.yexmp.2015.03.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
9 Xu C, Guo Y, Liu H, Chen G, Yan Y, Liu T. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Cell Biosci 2018;8:61. [PMID: 30519392 DOI: 10.1186/s13578-018-0260-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
10 Tan Y, Lu X, Cheng Z, Pan G, Liu S, Apiziaji P, Wang H, Zhang J, Abulimiti Y. miR-148a Regulates the Stem Cell-Like Side Populations Distribution by Affecting the Expression of ACVR1 in Esophageal Squamous Cell Carcinoma. Onco Targets Ther 2020;13:8079-94. [PMID: 32904700 DOI: 10.2147/OTT.S248925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
11 Fu X, Tian J, Zhang L, Chen Y, Hao Q. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells. FEBS Lett. 2012;586:1279-1286. [PMID: 22465665 DOI: 10.1016/j.febslet.2012.03.006] [Cited by in Crossref: 125] [Cited by in F6Publishing: 119] [Article Influence: 12.5] [Reference Citation Analysis]
12 Monroig PDC, Calin GA. Drug–MicroRNA Cross-Talk. MicroRNA in Regenerative Medicine. Elsevier; 2015. pp. 991-1016. [DOI: 10.1016/b978-0-12-405544-5.00038-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 David S, Meltzer SJ. MicroRNA involvement in esophageal carcinogenesis. Curr Opin Pharmacol. 2011;11:612-616. [PMID: 21992930 DOI: 10.1016/j.coph.2011.09.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
14 Yin H, He H, Cao X, Shen X, Han S, Cui C, Zhao J, Wei Y, Chen Y, Xia L, Wang Y, Li D, Zhu Q. MiR-148a-3p Regulates Skeletal Muscle Satellite Cell Differentiation and Apoptosis via the PI3K/AKT Signaling Pathway by Targeting Meox2. Front Genet 2020;11:512. [PMID: 32582277 DOI: 10.3389/fgene.2020.00512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Joshi P, Jeon YJ, Laganà A, Middleton J, Secchiero P, Garofalo M, Croce CM. MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. Proc Natl Acad Sci U S A 2015;112:8650-5. [PMID: 26124099 DOI: 10.1073/pnas.1500886112] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
16 Matuszcak C, Haier J, Hummel R, Lindner K. MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014; 20(38): 13658-13666 [PMID: 25320504 DOI: 10.3748/wjg.v20.i38.13658] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
17 Janiszewska J, Szaumkessel M, Szyfter K. microRNAs are important players in head and neck carcinoma: a review. Crit Rev Oncol Hematol 2013;88:716-28. [PMID: 23948550 DOI: 10.1016/j.critrevonc.2013.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
18 Berman M, Mattheolabakis G, Suresh M, Amiji M. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery. Expert Opinion on Drug Delivery 2016;13:987-98. [DOI: 10.1080/17425247.2016.1178236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Sun N, Wang C, Sun Y, Ruan Y, Huang Y, Su T, Zhou X, Huang H, Guo W, He M, Yao R, Lin X. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomedicine & Pharmacotherapy 2018;106:267-74. [DOI: 10.1016/j.biopha.2018.06.093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
20 Sharma P, Saraya A, Gupta P, Sharma R. Decreased levels of circulating and tissue miR-107 in human esophageal cancer. Biomarkers 2013;18:322-30. [DOI: 10.3109/1354750x.2013.781677] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
21 Eichelmann AK, Matuszcak C, Lindner K, Haier J, Hussey DJ, Hummel R. Complex role of miR-130a-3p and miR-148a-3p balance on drug resistance and tumor biology in esophageal squamous cell carcinoma. Sci Rep 2018;8:17553. [PMID: 30510209 DOI: 10.1038/s41598-018-35799-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ma W, Zhang X, Chai J, Chen P, Ren P, Gong M. Circulating miR-148a is a significant diagnostic and prognostic biomarker for patients with osteosarcoma. Tumor Biol 2014;35:12467-72. [DOI: 10.1007/s13277-014-2565-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
23 Takahashi M, Cuatrecasas M, Balaguer F, Hur K, Toiyama Y, Castells A, Boland CR, Goel A. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One. 2012;7:e46684. [PMID: 23056401 DOI: 10.1371/journal.pone.0046684] [Cited by in Crossref: 100] [Cited by in F6Publishing: 106] [Article Influence: 10.0] [Reference Citation Analysis]
24 Tian J, Shang M, Shi SB, Han Y, Xu J. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma. Cancer Chemother Pharmacol 2015;76:829-34. [PMID: 26330330 DOI: 10.1007/s00280-015-2854-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
25 Wang J, Cui Q. Specific Roles of MicroRNAs in Their Interactions with Environmental Factors. J Nucleic Acids 2012;2012:978384. [PMID: 23209884 DOI: 10.1155/2012/978384] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
26 Fang YF, Geng Q. Research progress and prospects of esophageal cancer in era of precision medicine. Shijie Huaren Xiaohua Zazhi 2017; 25(32): 2829-2837 [DOI: 10.11569/wcjd.v25.i32.2829] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
27 Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6:1179-86. [PMID: 26516367 DOI: 10.7150/jca.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
28 Wang Y, Zhao Y, Herbst A, Kalinski T, Qin J, Wang X, Jiang Z, Benedix F, Franke S, Wartman T, Camaj P, Halangk W, Kolligs FT, Jauch KW, Nelson PJ, Bruns CJ. miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. Ann Surg 2016;264:804-14. [PMID: 27501171 DOI: 10.1097/SLA.0000000000001928] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
29 Zhang J, Ying ZZ, Tang ZL, Long LQ, Li K. MicroRNA-148a promotes myogenic differentiation by targeting the ROCK1 gene. J Biol Chem. 2012;287:21093-21101. [PMID: 22547064 DOI: 10.1074/jbc.m111.330381] [Cited by in Crossref: 95] [Cited by in F6Publishing: 67] [Article Influence: 9.5] [Reference Citation Analysis]
30 Mayne GC, Hussey DJ, Watson DI. Can miRNA profiling allow us to determine which patients with esophageal cancer will respond to chemoradiotherapy? Expert Rev Anticancer Ther 2013;13:271-3. [PMID: 23477513 DOI: 10.1586/era.12.182] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Zangouei AS, Moghbeli M. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes Environ 2021;43:21. [PMID: 34099061 DOI: 10.1186/s41021-021-00192-4] [Reference Citation Analysis]
32 Corcoran C, Rani S, O'Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate 2014;74:1320-34. [PMID: 25053345 DOI: 10.1002/pros.22848] [Cited by in Crossref: 115] [Cited by in F6Publishing: 117] [Article Influence: 14.4] [Reference Citation Analysis]
33 Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J, Hummel R. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73. [PMID: 25175076 DOI: 10.1186/s13046-014-0073-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
34 Chen MJ, Cheng YM, Chen CC, Chen YC, Shen CJ. MiR-148a and miR-152 reduce tamoxifen resistance in ER+ breast cancer via downregulating ALCAM. Biochem Biophys Res Commun 2017;483:840-6. [PMID: 28063929 DOI: 10.1016/j.bbrc.2017.01.012] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
35 Chen X, Wang YW, Gao P. SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer. J Exp Clin Cancer Res 2018;37:100. [PMID: 29743122 DOI: 10.1186/s13046-018-0748-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
36 Song S, Ajani JA. The role of microRNAs in cancers of the upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2013;10:109-18. [PMID: 23165235 DOI: 10.1038/nrgastro.2012.210] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 7.0] [Reference Citation Analysis]
37 Tanaka K, Miyata H, Sugimura K, Fukuda S, Kanemura T, Yamashita K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis. 2015;36:894-903. [PMID: 26026166 DOI: 10.1093/carcin/bgv067] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 11.1] [Reference Citation Analysis]
38 Hong L, Han Y, Yang J, Zhang H, Zhao Q, Wu K, Fan D. MicroRNAs in gastrointestinal cancer: prognostic significance and potential role in chemoresistance. Expert Opin Biol Ther. 2014;14:1103-1111. [PMID: 24707835 DOI: 10.1517/14712598.2014.907787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
39 Chen Q, Luo G, Zhang X. MiR-148a modulates HLA-G expression and influences tumor apoptosis in esophageal squamous cell carcinoma. Exp Ther Med 2017;14:4448-52. [PMID: 29067119 DOI: 10.3892/etm.2017.5058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
40 Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35-47.e2. [PMID: 22580099 DOI: 10.1053/j.gastro.2012.05.003] [Cited by in Crossref: 118] [Cited by in F6Publishing: 131] [Article Influence: 11.8] [Reference Citation Analysis]
41 Butz F, Eichelmann AK, Mayne GC, Wang T, Bastian I, Chiam K, Marri S, Sykes PJ, Wijnhoven BP, Toxopeus E, Michael MZ, Karapetis CS, Hummel R, Watson DI, Hussey DJ. MicroRNA Profiling in Oesophageal Adenocarcinoma Cell Lines and Patient Serum Samples Reveals a Role for miR-451a in Radiation Resistance. Int J Mol Sci 2020;21:E8898. [PMID: 33255413 DOI: 10.3390/ijms21238898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Plum PS, Bollschweiler E, Hölscher AH, Warnecke-Eberz U. Novel diagnostic and prognostic biomarkers in esophageal cancer. Expert Opin Med Diagn 2013;7:557-71. [PMID: 24093836 DOI: 10.1517/17530059.2013.843526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
43 Sui C, Meng F, Li Y, Jiang Y. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J Transl Med 2015;13:132. [PMID: 25927928 DOI: 10.1186/s12967-015-0488-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
44 Rukov JL, Wilentzik R, Jaffe I, Vinther J, Shomron N. Pharmaco-miR: linking microRNAs and drug effects. Brief Bioinform 2014;15:648-59. [PMID: 23376192 DOI: 10.1093/bib/bbs082] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 10.6] [Reference Citation Analysis]
45 Lindner K, Eichelmann AK, Matuszcak C, Hussey DJ, Haier J, Hummel R. Complex Epigenetic Regulation of Chemotherapy Resistance and Biohlogy in Esophageal Squamous Cell Carcinoma via MicroRNAs. Int J Mol Sci 2018;19:E499. [PMID: 29414899 DOI: 10.3390/ijms19020499] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
46 Odenthal M, Bollschweiler E, Grimminger P, Schröder W, Brabender J, Drebber U, Hölscher A, Metzger R, Vallböhmer D. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response: MicroRNA profiling in esophageal cancer. Int J Cancer 2013;133:2454-63. [DOI: 10.1002/ijc.28253] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
47 Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P, Torrisani J. The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool. PLoS One. 2013;8:e55513. [PMID: 23383211 DOI: 10.1371/journal.pone.0055513] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
48 Li X, Wainscott C, Xi Y. MicroRNA provides insight into understanding esophageal cancer: MicroRNA and esophageal cancer. Thoracic Cancer 2011;2:134-42. [DOI: 10.1111/j.1759-7714.2011.00059.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
49 Reuter T, Herold-Mende C, Dyckhoff G, Rigalli JP, Weiss J. Functional role of miR-148a in oropharyngeal cancer: influence on pregnane X receptor and P-glycoprotein expression. J Recept Signal Transduct Res 2019;39:451-9. [PMID: 31771390 DOI: 10.1080/10799893.2019.1694541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Li Y, Deng X, Zeng X, Peng X. The Role of Mir-148a in Cancer. J Cancer 2016;7:1233-41. [PMID: 27390598 DOI: 10.7150/jca.14616] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
51 Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, Westhead D, Alder JE, Shaw L, Short SC, Lawler SE. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol 2015;9:704-14. [PMID: 25499534 DOI: 10.1016/j.molonc.2014.11.004] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
52 Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23:512-521. [PMID: 24013023 DOI: 10.1016/j.semcancer.2013.08.005] [Cited by in Crossref: 73] [Cited by in F6Publishing: 78] [Article Influence: 8.1] [Reference Citation Analysis]
53 Hemmatzadeh M, Mohammadi H, Karimi M, Musavishenas MH, Baradaran B. Differential role of microRNAs in the pathogenesis and treatment of Esophageal cancer. Biomed Pharmacother. 2016;82:509-519. [PMID: 27470391 DOI: 10.1016/j.biopha.2016.05.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
54 Matuszcak C, Lindner K, Eichelmann AK, Hussey DJ, Haier J, Hummel R. microRNAs: Key regulators of chemotherapy response and metastatic potential via complex control of target pathways in esophageal adenocarcinoma. Surg Oncol 2018;27:392-401. [PMID: 30217293 DOI: 10.1016/j.suronc.2018.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Tian Y, Sun C, Zhang L, Pan Y. Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy. Cancer Biol Med 2018;15:157-64. [PMID: 29951339 DOI: 10.20892/j.issn.2095-3941.2017.0182] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
56 Bailly C. Anticancer properties and mechanism of action of the quassinoid ailanthone. Phytother Res 2020;34:2203-13. [PMID: 32239572 DOI: 10.1002/ptr.6681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
57 Chen X, Wu QF, Yan GY. RKNNMDA: Ranking-based KNN for MiRNA-Disease Association prediction. RNA Biol 2017;14:952-62. [PMID: 28421868 DOI: 10.1080/15476286.2017.1312226] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 18.2] [Reference Citation Analysis]
58 Jingjing L, Wangyue W, Qiaoqiao X, Jietong Y. MiR-218 increases sensitivity to cisplatin in esophageal cancer cells via targeting survivin expression. Open Med (Wars) 2016;11:31-5. [PMID: 28352763 DOI: 10.1515/med-2016-0007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
59 Dashti F, Mirazimi SMA, Rabiei N, Fathazam R, Rabiei N, Piroozmand H, Vosough M, Rahimian N, Hamblin MR, Mirzaei H. The role of non-coding RNAs in chemotherapy for gastrointestinal cancers. Mol Ther Nucleic Acids 2021;26:892-926. [PMID: 34760336 DOI: 10.1016/j.omtn.2021.10.004] [Reference Citation Analysis]
60 Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, Ryu DY, Lee BE, Kim HH. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn. 2013;15:661-669. [PMID: 23806809 DOI: 10.1016/j.jmoldx.2013.04.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
61 Yang W, Ma J, Zhou W, Zhou X, Cao B, Zhang H, Zhao Q, Fan D, Hong L. Molecular mechanisms and clinical implications of miRNAs in drug resistance of esophageal cancer. Expert Rev Gastroenterol Hepatol 2017;11:1151-63. [PMID: 28838272 DOI: 10.1080/17474124.2017.1372189] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
62 Buckley AM, Bibby BA, Dunne MR, Kennedy SA, Davern MB, Kennedy BN, Maher SG, O'Sullivan J. Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells. Pharmaceuticals (Basel) 2019;12:E33. [PMID: 30791601 DOI: 10.3390/ph12010033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
63 Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C, Xu W. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013;45:963-972. [PMID: 24108762 DOI: 10.1093/abbs/gmt106] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
64 Vimalraj S, Selvamurugan N. MicroRNAs expression and their regulatory networks during mesenchymal stem cells differentiation toward osteoblasts. International Journal of Biological Macromolecules 2014;66:194-202. [DOI: 10.1016/j.ijbiomac.2014.02.030] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 7.6] [Reference Citation Analysis]
65 Sharma P, Sharma R. miRNA-mRNA crosstalk in esophageal cancer: From diagnosis to therapy. Crit Rev Oncol Hematol. 2015;96:449-462. [PMID: 26257289 DOI: 10.1016/j.critrevonc.2015.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
66 Hummel R, Sie C, Watson DI, Wang T, Ansar A, Michael MZ, Hoek MVD, Haier J, Hussey DJ. MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J Gastroenterol 2014; 20(40): 14904-14912 [PMID: 25356050 DOI: 10.3748/wjg.v20.i40.14904] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
67 Boonstra JJ, Tilanus HW, Dinjens WN. Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis Esophagus 2015;28:90-6. [PMID: 23795680 DOI: 10.1111/dote.12095] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
68 Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 2012;64:706-21. [PMID: 22659329 DOI: 10.1124/pr.111.005637] [Cited by in Crossref: 468] [Cited by in F6Publishing: 459] [Article Influence: 46.8] [Reference Citation Analysis]
69 Yang H, Hou H, Zhao H, Yu T, Hu Y, Hu Y, Guo J. HK2 Is a Crucial Downstream Regulator of miR-148a for the Maintenance of Sphere-Forming Property and Cisplatin Resistance in Cervical Cancer Cells. Front Oncol 2021;11:794015. [PMID: 34858863 DOI: 10.3389/fonc.2021.794015] [Reference Citation Analysis]